| Budget Amount *help |
¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2019: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
That this problem cancels anticancer drug treatment appropriately didn't affect the convalescence of the patient and in fact made the thing which contributes to QOL improvement a hypothesis. An observation study by a multicenter joint research group is begun targeted for the progress lung cancer patient taking molecular target medicine as the last treatment, and a case beyond 100 examples is accumulated and is continuing for 200 examples of a target in the present. The calculation and kou by which which is the medical cost after convalescence bad factor arrival, oh, it's made basic data of the positive intervention study which analyzes treatment continuation including an economic impact, and is after that. On the other hand it was possible to indicate the patient crowd who can think it's useful to do a retrospective study about the treatment reality of the end terminal cancer patient apart from the above observation study and receive chemotherapy in spite of the end period.
|
